Company: ICUI
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000883984-25-000007
Chunk: 199

Company: ICU MEDICAL INC/DE
Filing Date: 2025-02-27
Form: 10-K
Item: Item 1
Chunk 199
---
809 $27,504 Cash paid during the year for interest$99,717 $95,913 $63,713 SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES:Accounts payable for property, plant and equipment$7,443 $6,570 $4,854   Detail of assets acquired and liabilities assumed in acquisitions:Fair value of assets acquired$1,606,300 Cash paid for acquisitions, net of cash acquired(1,844,164)Issuance of common stock for acquisitions(575,975)Contingent consideration(55,158)Goodwill, acquired/adjusted during period1,462,752           Liabilities assumed/Adjustments to liabilities assumed$593,755 

The accompanying notes are an integral part of these consolidated financial statements.

67

ICU MEDICAL, INC. AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations ICU Medical, Inc. ("ICU" or "we"), a Delaware corporation, develops, manufactures and sells innovative medical products used in infusion therapy, vascular access, and vital care applications. ICU's product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. We sell the majority of our products globally through our direct sales force and through independent distributors throughout the U.S. and internationally. We also sell certain products on an original equipment manufacturer basis to other medical device manufacturers.Basis of PresentationAll subsidiaries are wholly owned and are included in the consolidated financial statements. All intercompany balances and transactions have been eliminated. Results of operations of companies purchased are included from the dates of acquisition.The consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation.  These consolidated financial statements were prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP").  Certain reclassifications have been made to the prior year financial statements and footnotes to conform to the presentation used in the current year. In the consolidated statements of cash flows, we reclassified bond premium amortization to other.